Display Settings:

Format

Send to:

Choose Destination
    J Clin Invest. 2012 Jan 3;122(1):19-22. doi: 10.1172/JCI61453. Epub 2011 Dec 19.

    Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer.

    Source

    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

    Abstract

    Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases. Hence, great efforts have been made to develop drugs targeting the EET pathway. Some of these agents are currently under evaluation in clinical trials for treatment of hypertension and diabetes. In this issue of the JCI, Panigrahy et al. evaluate in a systematic way the role of CYP epoxygenases and the metabolites they generate in cancer progression. Their findings, along with previous studies, raise concerns about using these drugs in humans.

    PMID:
    22182836
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3248310
    [Available on 2012/12/31]

      Supplemental Content

      Icon for Journal of Clinical Investigation

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk